Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ALOX5AP | P20292 | 13/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7196031 | 0.92 | MRGPRX4 (0.42) | MRGPRX4LMNAGAAALOX5APOPRL1 | |
| SCHEMBL6488591 | 0.92 | ALOX5AP (0.44) | ALOX5APOPRL1 | |
| SCHEMBL6487299 | 0.88 | MRGPRX4 (0.42) | MRGPRX4LMNAGAAMAPTALDH1A1 | |
| SCHEMBL6489607 | 0.81 | MEN1 (0.41) | MRGPRX4LMNAGAAMAPTALDH1A1 | |
| SCHEMBL6488968 | 0.81 | PPARG (0.50) | LMNAALOX5APOPRL1MAPTHPGD | |
| SCHEMBL6488861 | 0.80 | BCL2 (0.44) | MRGPRX4TDP1 | |
| SCHEMBL6490952 | 0.80 | ALOX5AP (0.43) | GAAALOX5APALDH1A1NPSR1 | |
| SCHEMBL6500991 | 0.79 | ALOX5AP (0.42) | ALOX5APOPRL1MAPTALDH1A1 | |
| SCHEMBL6497506 | 0.78 | PDE3B (0.43) | ALOX5APALDH1A1HPGDNPSR1 | |
| SCHEMBL6488710 | 0.78 | BCL2 (0.39) | OPRL1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | MRGPRX4 2443/4885LMNA 3711/4885GAA 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.